Chinnabhandar V, Verneris MR, Schultz KR, Gamis AS, Aplenc R, Hudson CA, Alonzo TA, Gerbing RB, Horan JT, Chewning JH. HLA-DR expression at diagnosis is not predictive of relapse risk post allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a report from the Children’s Oncology Group. Haematologica. 2026 Sep 1;111(9):3093-3096. doi: 10.3324/haematol.2025.288751. Epub 2026 Mar 26. PMID: 41885017; PMCID: PMC13530937.
Publication Citation
Abstract
The therapeutic role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with relapsed, refractory, or high-risk acute myeloid leukemia (AML) in first remission is well-recognized. It remains the best curative option for these groups of patients. However, relapse after allo-HSCT remains a significant challenge, seen in up to 40-50% of transplant recipients.